- ¥2980
- LMAI Bio
- LM-3090R-FITC
- 中国/美国/欧洲
- 2025年07月15日
- IF=1:50-200
- Human, Mouse, Rat, Chicken, Pig, Rabbit, Sheep,
- Human, Mouse, Rat, Chicken, Pig, Rabbit, Sheep,
10 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
上海联迈生物工程有限公司
- 库存：
大量
- 靶点：
详见说明书
- 级别：
1
- 目录编号：
LM-3090R-FITC
- 克隆性：
多克隆
- 抗原来源：
Rabbit
- 保质期：
1年
- 抗体英文名：
Anti-phospho-CBL2 (Tyr774)/FITC
- 抗体名：
Anti-phospho-CBL2 (Tyr774)/FITC
- 标记物：
FITC标记
- 宿主：
Human, Mouse, Rat, Chicken, Pig, Rabbit, Sheep,
- 适应物种：
Human, Mouse, Rat, Chicken, Pig, Rabbit, Sheep,
- 免疫原：
详见说明书
- 亚型：
IGg
- 形态：
粉末、液体、冻干粉
- 应用范围：
IF=1:50-200
- 浓度：
1mg/ml
- 保存条件：
-20 °C
- 规格：
100ul
FITC标记的磷酸化原癌蛋白CBL2抗体
| 英文名称 | Anti-phospho-CBL2 (Tyr774)/FITC |
| 中文名称 | FITC标记的磷酸化原癌蛋白CBL2抗体 |
| 别 名 | CBL2 (phospho-Tyr774); CBL2 (phospho-Y774); p-CBL2 (Tyr774); p-CBL2 (Y774); C CBL; Cas-Br-M (murine) ecotropic retroviral transforming sequence; Casitas B lineage lymphoma proto oncogene; CBL 2;E3 ubiquitin protein ligase CBL; Oncogene CBL2; Proto oncogene c CBL; RGD1561386; RING finger protein 55; RNF55v Signal transduction protein CBL; 4732447J05Rik; CBL_HUMAN. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 产品类型 | 磷酸化抗体 |
| 研究领域 | 肿瘤 细胞生物 免疫学 信号转导 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Chicken, Pig, Rabbit, Sheep, |
| 产品应用 | IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 100kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human CBL2 around the phosphorylation site of Tyr774 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Mar 2012] Function: Adapter protein that functions as a negative regulator of many signaling pathways that are triggered by activation of cell surface receptors. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling. Recognizes membrane-bound HCK and other kinases of the SRC family and mediates their ubiquitination and degradation. Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis. Essential for osteoclastic bone resorption. The Tyr-731 phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Subunit: Interacts (phosphorylated at Tyr-731) with PIK3R1. Associates with NCK via its SH3 domain. The phosphorylated C-terminus interacts with CD2AP via its second SH3 domain. Binds to UBE2L3. Interacts with adapters SLA, SLA2 and with the phosphorylated C-terminus of SH2B2. Interacts with EGFR, SYK and ZAP70 via the highly conserved Cbl-N region. Also interacts with SORBS1 and INPPL1/SHIP2. Interacts with phosphorylated LAT2. May interact with CBLB (By similarity). Interacts with ALK, AXL, BLK, FGR and FGFR2. Interacts with CSF1R, EPHB1, FLT1, KDR, PDGFRA and PDGFRB; regulates receptor degradation through ubiquitination. Interacts with HCK and LYN. Interacts with TEK/TIE2 (tyrosine phosphorylated). Subcellular Location: Cytoplasm. Cell membrane. Note=Colocalizes with FGFR2 in lipid rafts at the cell membrane. Post-translational modifications: Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues in response to FLT1 and KIT signaling. Phosphorylated on tyrosine residues by INSR and FGR. Phosphorylated on several tyrosine residues by constitutively activated FGFR3. Not phosphorylated at Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by HCK. Ubiquitinated, leading to its degradation via the proteasome. DISEASE: Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia (NSLL) [MIM:613563]: A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain. Contains 1 RING-type zinc finger. Contains 1 UBA domain. Database links: Entrez Gene: 867 Human Entrez Gene: 12402 Mouse Entrez Gene: 500985 Rat Omim: 165360 Human SwissProt: P22681 Human SwissProt: P22682 Mouse Unigene: 504096 Human Unigene: 266871 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CBL2(Casitas B-lineage lymphoma)是一类广泛分布的细胞内蛋白,属于泛素连接酶E3, Cbl参与细胞内信号转导的负向调控,这对于维持细胞的内稳态具有重要作用。Cbl突变后可成为癌蛋白;许多肿瘤细胞则表现为与增殖有关的分子(如受体型蛋白酪氨酸激酶,RTK)因发生突变或其它遗传学改变不受Cbl负调控。加强或重建Cbl的负调控作用,或许能够从受体活化的上游信号开始抑制肿瘤细胞增殖。为利用Cbl的泛素连接酶活性,并使其能够特异性地降解某些信号转导分子,从而对一些与肿瘤生长有关的细胞增殖进行负向调节 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
特异性的选择主要需要考虑四个方面：蛋白特异性、种属特异性、实验方法特异性、标记物的特异性。 （1）蛋白特异性 针对需要检测的蛋白查找抗体，几个细节要区分，重组表达的蛋白和内源性蛋白的检测，对抗体的要求是不一样的，注意查看抗体说明书的检测说明。如果重组蛋白不是全长表达，则需要注意抗体的免疫原区域是否在重组蛋白区域内。内源性蛋白最好能清楚其剪切与修饰的方式，特殊表型的蛋白需要进行序列比对，并结合抗体免疫原序列，查看交叉反应的情况。磷酸化蛋白检测需要确定具体位点，不同位点的磷酸化意味
HistostainTM－plus kits 检测AT2R的问题 【求助】整合素的免疫组化阳性照片 【求助】关于免疫组化方法的选择 【求助】谁有抗体染内体或溶酶体的图片，能发一个吗？ 【求助】流式用荧光抗体能用于原位荧光显色吗? 【请教】偏酸性条件下FITC的标记效率 【求助】神经元标志物 【求助】求助：关于非特异性染色 【请教】EGFR的免疫组化 【请教】免疫荧光的封片剂 【请教】关于免疫组化的结果分析 【请教】用豚鼠建立模型，买抗体是买针对小鼠还是大鼠
, PS）正常位于细胞膜的内侧，但在细胞凋亡的早期，PS可从细胞膜的内侧翻转到细胞膜的表面，暴露在细胞外环境中(图3)。Annexin-V是一种分子量为35~36KD的Ca2+依赖性磷脂结合蛋白，能与PS高亲和力特异性结合。将Annexin-V进行荧光素（FITC、PE）或biotin标记，以标记了的Annexin-V作为荧光探针，利用流式细胞仪或荧光显微镜可检测细胞凋亡的发生。碘化丙啶(propidine iodide, PI)是一种核酸染料，它不能透过完整的细胞膜，但在凋亡中晚期的细胞和死细胞
技术资料暂无技术资料 索取技术资料
FITC标记的磷酸化原癌蛋白CBL2抗体
¥2980
